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A NOTE ON THE LACK OF CARCINOGENIC ACTION OF
SOME CARDIAC GLUCOSIDES AND SAPONINS*
PAUL K. SMITH AND WILLIAM U. GARDNER
The demonstration that the long-continued administration of
certain sex hormones results in the production of malignant changes
in mice, 2, 4, 6 suggested that other compounds of cydopentenophen-
anthrene structure should be studied for similar effects. The
cardiac glucosides and saponins were chosen because they present cer-
tain variations in molecular structure not found in the sex hormones,
bile acids, or sterols.3 The cardiac glucosides are extremely toxic
to most mammals, but the observations of Hatcher' indicated that
rodents could tolerate fairly large doses.
In this work, with a few exceptions, male mice of a strain with
a low incidence of cancer were used. The compounds to be tested
were dissolved or suspended in sesame oil, 10 mg. per cc. of oil, and
injected subcutaneously twice weekly up to a total dose of 10 mg.
Some of the compounds were so toxic that many of the mice died
after a single dose (1 mg.). This does not imply that mice are
intolerant to these drugs, since with many of them 1 mg. is an
average dose for the adult man.
Several of the compounds (notably digitoxin) are said to be very
irritating upon subcutaneous injection, but in these experiments only
one compound, the saponin digitonin, was found to be extremely so.
It produced such severe tissue damage at the site of injection, that
a number of the animals died before the series of injections could
be completed.
The compounds given, the number of mice used, and the number
ofdays of survival are listed in the table. Only mice surviving 100
days or more are induded.
Two of the mice which received strophanthidin had litters.
Somewhat later a mammary carcinoma developed in one of these
and at autopsy a small lung tumor was found. The other mouse
developed a tumor which was successfully transplanted and his-
tologically shown to be a mammary carcinoma. As females of this
strain, particularly those that have had young, develop spontaneous
mammary tumors this finding was not regarded as evidence that
strophanthin exhibited a carcinogenic effect.
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Total number No. survvng more Range ofsurvid,
Substance tested ofmce than 100 days in days
Ouabain ........... .............. 7 1 334
Cymarin* ......................... 2 0 ......
Strophanthin-k* ......................... 2 1 322
Strophanthidin ......................... 10 7 241-708
Digitoxin ......................... 2 1. 408
Scillaren A ............... .......... 6 5 246-458
Bufagin ........... .............. 4 1 665
Cinobufagin ......................... 2 0 ......
Bufotalin ............. ............ 8 2 323-448
Bufotoxint..........................1 1 480
Uzarin .......... ............... 6 6 508-679
Digitonin ......................... 10 6 159-597
Sarsasapogenin ......................... 11 6 333-642
*The aglycone of these is strophanthidin. t The aglycone of this is bufotalin.
None of the other mice developed tumors of any kind, either at
the point of injection or in parenchymatous organs. Due to the
high toxicity of the drugs, and in several cases because of a lack of
available material, it was possible to study only a small number of
animals, but at best it seems probable that the compounds studied
can not be regarded as belonging to the group of powerful car-
cinogens. The limitations of the present study can not exdude the
possibility of mild carcinogenic properties. The principal difference
in molecular structure between the above-mentioned compounds and
similar compounds known to be carcinogenic lies perhaps in the
small number ofunsaturated linkages in the glucosides and saponins.
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